Humana Quarterly Loss Signals Payer Margin Strain
Healthcare providers and vendors dependent on managed-care payers should watch whether medical cost pressure shows up in Humana's results.
Updated on Nov. 6, 2026 in Healthcare
Humana Inc., the Louisville, Kentucky-based health insurer, will release its third-quarter earnings before the market opens Friday, Nov. 6. Analysts expect a quarterly loss of $1.00 per share, compared with $3.24 per share in profit a year earlier.
Why it matters
The report arrives as several analysts have raised price targets and one upgraded the stock to Outperform, leaving expectations high even as Humana is projected to post a loss. For operators in healthcare and insurance-adjacent businesses, the quarter offers a read on how managed-care economics are holding up.
Analysts expect Humana to post a quarterly loss of $1.00 per share against $3.24 per share a year earlier, on consensus revenue of $40.89 billion versus $32.65 billion last year. Humana shares closed Thursday at $411.79, down 1.4%, and the board declared a cash dividend of 88.5 cents per share on Oct. 29.
The players
Humana Inc.
Louisville, Kentucky-based health insurer that sells Medicare Advantage and other managed-care plans and is judged by its medical cost ratios and membership growth.
Mizuho
Global financial group whose equity research arm covers U.S. managed-care stocks and issued an Outperform rating on Humana.
UBS
Global investment bank whose analyst maintained a Neutral rating on Humana while raising its price target.
Raymond James
U.S. brokerage and investment bank whose analyst upgraded Humana to Outperform on Oct. 12, 2026.
The details
Analyst estimates are the benchmark against which the Friday report will be judged, so a result that differs from the expected $1.00 loss will move expectations quickly. Four firms revised price targets between Oct. 12 and Oct. 13, with Mizuho and UBS setting targets of $495, Oppenheimer at $525, and Raymond James at $520 after its upgrade. Those revisions suggest analysts are pricing in a recovery narrative that the upcoming numbers will either support or challenge.
Timeline
Oct. 12, 2026: Raymond James upgraded Humana to Outperform and three firms revised price targets.
Oct. 13, 2026: Mizuho raised its price target to $495.
Oct. 29, 2026: Humana declared an 88.5-cent cash dividend per share.
Thursday, Nov. 5, 2026: Humana shares closed at $411.79, down 1.4%.
Friday, Nov. 6, 2026: Humana releases third-quarter earnings before the market opens.
Market Landscape
Humana's earnings sit within the federal Medicare Advantage payment framework administered by the Centers for Medicare & Medicaid Services, which determines how much insurers receive per enrollee. The expected swing from a $3.24 profit to a $1.00 loss puts the company's medical-cost management under direct scrutiny against that backdrop.
Operators in healthcare services and vendors serving insurers should watch whether medical cost trends behind the expected loss are easing or worsening, since that shapes payer demand for services. Procurement and finance teams with exposure to managed-care contracts may want to review payment timing and reimbursement assumptions once the results are public.
The takeaway
Track the third-quarter medical cost ratio and any forward guidance Humana provides on Nov. 6, because those figures will show whether the expected loss reflects temporary pressure or a deeper margin problem. Compare the results against analyst consensus of a $1.00 loss before adjusting any payer-dependent revenue forecasts.
What happens next
Humana is scheduled to release its third-quarter earnings before the market opens on Friday, Nov. 6, 2026.
Further reading
For broader context on how payers are reshaping their finances, see the Healthcare coverage on We are Main Street.
